2022
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, Lopez-Rios F, Tsao MS, Yatabe Y, Beasley MB, Yu H, Sholl LM, Brambilla E, Chou TY, Connolly C, Wistuba I, Kerr KM, Lantuejoul S, Committee I. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. Journal Of Thoracic Oncology 2022, 17: 1335-1354. PMID: 36184066, DOI: 10.1016/j.jtho.2022.09.109.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsTumor mutational burdenLung Cancer Pathology CommitteePD-L1 immunohistochemistryPredictive biomarkersImmunotherapy biomarkersLung cancerPathology CommitteeBackbone of treatmentSubset of patientsMost lung cancersEarly-stage tumorsCompanion diagnostic assayAdjuvant settingNeoadjuvant immunotherapyCheckpoint inhibitorsMetastatic diseasePathologic responseImmune microenvironmentStage tumorsMutational burdenImmunotherapyPrognosis predictionImmunohistochemistryBiomarkersCharacterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, C. P, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B. Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing. JTO Clinical And Research Reports 2022, 3: 100381. PMID: 36082279, PMCID: PMC9445394, DOI: 10.1016/j.jtocrr.2022.100381.Peer-Reviewed Original ResearchWhole transcriptome sequencingTranscriptome sequencingSplice siteMet stabilityDonor splice siteNext-generation sequencingTranscriptomic levelSplicing alterationsEnrichment analysisJunction pathwayPoint mutationsPotential therapeutic targetGenomic alterationsRNA expressionSequencingGene signaturePathwayMutational burdenGenomic profilingSynergistic increaseExpressionMost alterationsCheckpointTherapeutic targetSingle-sample gene
2021
The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis.
Klebe S, Nakatani Y, Dobra K, Butnor KJ, Roden AC, Nicholson AG, Marchevsky AM, Husain AN, Segal A, Walts AE, Weynand B, Michael CW, Dacic S, Godbolt D, Attanoos R, Santoni-Rugiu E, Galateau-Salle F, Hiroshima K, Moreira AL, Burn J, Nabeshima K, Gibbs AR, Churg A, Litzky LA, Brcic L, Tsao MS, Mino-Kenudson M, Rørvig SB, Tazelaar HD, Krausz T, Zhang YZ, Chirieac LR, Beasley MB, Hjerpe A. The concept of mesothelioma in situ, with consideration of its potential impact on cytology diagnosis. Pathology 2021, 53: 446-453. PMID: 33775406, DOI: 10.1016/j.pathol.2020.12.005.Peer-Reviewed Original Research
2020
Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology.
Roy-Chowdhuri S, Dacic S, Ghofrani M, Illei PB, Layfield LJ, Lee C, Michael CW, Miller RA, Mitchell JW, Nikolic B, Nowak JA, Pastis NJ, Rauch CA, Sharma A, Souter L, Billman BL, Thomas NE, VanderLaan PA, Voss JS, Wahidi MM, Yarmus LB, Gilbert CR. Collection and Handling of Thoracic Small Biopsy and Cytology Specimens for Ancillary Studies: Guideline From the College of American Pathologists in Collaboration With the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Archives Of Pathology & Laboratory Medicine 2020 PMID: 32401054, DOI: 10.5858/arpa.2020-0119-CP.Peer-Reviewed Original Research
2008
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc 2008, 21: 742-7. PMID: 18327208, DOI: 10.1038/modpathol.2008.45.Peer-Reviewed Original Research